BLUE BELL, Pa.
June 18, 2012
/PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) has appointed
, Ph.D., to its Board of Directors. Dr. Cabrera is outgoing president of the Thunderbird School of Global Management, widely regarded as the world's leading graduate school of international business. On
, Dr. Cabrera will become president of
George Mason University
, the largest university in
During his eight-year term, Dr. Cabrera led a major academic, operational and financial overhaul of the international business school, stemming operating deficits and declining revenues and consolidating Thunderbird's leadership position in the global business educational arena. Prior to Thunderbird, Cabrera served as Dean of IE Business School in
, which he helped propel into the top tier of international business schools. Prior to IE he was a change management consultant with Accenture.
earned his Ph.D. and M.S. in psychology and cognitive science from the
Georgia Institute of Technology
-- which he attended as a Fulbright Scholar -- and his B.S. and M.S. in computer and electrical engineering from
's Polytechnic University,
's premier engineering school. He received additional training in cognitive science at
Carnegie Mellon University
and in global leadership at the Harvard Kennedy School. He has published extensively in fields ranging from learning technology to psychology, management and higher education. His most recent book, "Being Global: How to Think, Act and Lead in a Transformed World," was recently published by Harvard Business Review Press. Dr. Cabrera is an advocate of corporate social responsibility and managerial professionalism.
J. Joseph Kim
, Inovio's president and CEO, said, "Inovio is honored to have Dr. Cabrera, a world renowned international business expert, bring his unique management and leadership experience to Inovio's Board. His insights will be valuable to Inovio's organizational development and in the strategic decision-making around the many technology and product development as well as partnering opportunities available to us as we advance our synthetic vaccines."
About Inovio Pharmaceuticals, Inc.
Inovio is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases. Its SynCon® vaccines are designed to provide universal cross-strain protection against known as well as newly emergent unmatched strains of pathogens such as influenza. These synthetic vaccines, in combination with Inovio's proprietary electroporation delivery, have been shown in humans to generate best-in-class immune responses with a favorable safety profile. Inovio's clinical programs include Phase II studies for cervical dysplasia, leukemia and hepatitis C virus and Phase I studies for influenza and HIV. Partners and collaborators include the
University of Pennsylvania
, Merck, ChronTech, National Cancer Institute, U.S. Military HIV Research Program, NIH, HIV Vaccines Trial Network, University of Southampton, US Dept. of Homeland Security and PATH Malaria Vaccine Initiative. More information is available at
This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2011, our Form 10-Q for the quarter ended March 31, 2012, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.
, Inovio Pharmaceuticals, 858-410-3101Media:
, Inovio Pharmaceuticals, 267-440-4211
SOURCE Inovio Pharmaceuticals, Inc.